Targeted drug trial offers hope for select pancreatic cancer patients
NCT ID NCT03601923
Summary
This study is testing whether the drug niraparib can help control advanced pancreatic cancer in patients whose tumors have specific genetic mutations affecting DNA repair. The trial is enrolling 32 adults whose cancer has progressed after at least one prior treatment and who have mutations in genes like BRCA1, BRCA2, or ATM. Researchers will measure how long the cancer remains stable without progressing and monitor side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.